Home » Stocks » NGM

NGM Biopharmaceuticals, Inc. (NGM)

Stock Price: $26.52 USD -1.42 (-5.08%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
After-hours: $27.26 +0.74 (2.79%) Jan 26, 7:26 PM
Market Cap 1.97B
Revenue (ttm) 98.68M
Net Income (ttm) -90.44M
Shares Out 68.82M
EPS (ttm) -1.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $26.52
Previous Close $27.94
Change ($) -1.42
Change (%) -5.08%
Day's Open 28.04
Day's Range 26.00 - 28.60
Day's Volume 337,571
52-Week Range 10.00 - 31.44

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 weeks ago

SOUTH SAN FRANCISCO, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative th...

GlobeNewsWire - 3 weeks ago

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative th...

GlobeNewsWire - 3 weeks ago

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative th...

GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative th...

GlobeNewsWire - 2 months ago

– Event to showcase NGM's multi-therapeutic area p ipeline , including its oncology por tfolio and Geographic Atrophy and NASH programs – 

GlobeNewsWire - 2 months ago

--Single and multiple intravitreal injections of NGM621 appeared safe and well tolerated in first-in-human study, with no patients experiencing serious adverse events, drug-related AEs, intrao...

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative th...

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative th...

Zacks Investment Research - 2 months ago

NGM Biopharmaceuticals (NGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative th...

GlobeNewsWire - 4 months ago

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative ...

GlobeNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative ...

Zacks Investment Research - 5 months ago

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of -15.15% and -3.25%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the...

GlobeNewsWire - 5 months ago

--Sustained progress across clinical development programs spanning liver,  retinal and metabolic diseases and cancer-- --Aldafermin continues to advance toward late-stage clinical developmen...

Zacks Investment Research - 5 months ago

NGM Biopharmaceuticals (NGM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research - 5 months ago

NGM Biopharmaceuticals (NGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., July 31, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative ...

GlobeNewsWire - 6 months ago

-- Multicenter, randomized, double-masked, sham-controlled study will evaluate safety and efficacy of intravitreal injections of NGM621 every four or eight weeks for 48 weeks -- -- GA is a pr...

Zacks Investment Research - 7 months ago

NGM Biopharmaceuticals (NGM) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

GlobeNewsWire - 7 months ago

SOUTH SAN FRANCISCO, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on developing transformative therapeutics for ...

Zacks Investment Research - 8 months ago

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 3.45% and 22.33%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the ...

GlobeNewsWire - 8 months ago

-- Initiated Phase 2b ALPINE 4 clinical study of aldafermin (formerly NGM282) in  non-alcoholic steatohepatitis (NASH) patients with compensated cirrhosis (F4 fibrosis) -- -- Continuing enr...

GlobeNewsWire - 8 months ago

SOUTH SAN FRANCISCO, Calif., May 08, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) today announced that, due to public health and safety concerns related to the coronav...

InvestorPlace - 9 months ago

Market watchers are looking to the insiders, hoping insights from their activity can steer them towards returns.

Other stocks mentioned: AXDX, CDLX, GIII, OPK
Benzinga - 9 months ago

NGM Biopharmaceuticals Inc (NASDAQ: NGM), which went public about a year back, has seen its shares trade mostly below the IPO price of $16.

GlobeNewsWire - 10 months ago

SOUTH SAN FRANCISCO, Calif., March 09, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on developing transformative therapeutics for pati...

The Motley Fool - 11 months ago

Strong results on multiple measures put the company's drug candidate firmly in the NASH discussion.

The Motley Fool - 11 months ago

Shares popped after the clinical-stage biotech reported upbeat clinical results.

Benzinga - 11 months ago

NGM Biopharmaceuticals Inc (NASDAQ: NGM) is advancing strongly on above-average volume Monday following a positive clinical data readout.

GlobeNewsWire - 11 months ago

--Study to evaluate potential of GDF15/GFRAL pathway inhibition to  block tumor-associated weight loss and tumor growth-- --CACS, an uncontrolled wasting syndrome, is a common co-morbidity of ...

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therape...

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor NGM Biopharmaceuticals.

Zacks Investment Research - 1 year ago

Here we highlight five biotech companies, which are expected to deliver positive earnings surprises in this earnings season.

Other stocks mentioned: ACIU, ASND, EYEN, SAGE
Seeking Alpha - 1 year ago

NGM Biopharmaceuticals announces positive data from Phase 2b study treating patients with NASH using NGM282.

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Oct. 18, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therape...

The Motley Fool - 1 year ago

Tough industry conditions and company-specific issues hit these stocks.

Other stocks mentioned: ACB, SRNE

About NGM

NGM Biopharmaceuticals, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include Aldafermin, an engineered variant of the FGF19 human hormone in Phase 2b clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b clinical trial for use in the tr... [Read more...]

Industry
Biotechnology
IPO Date
Apr 4, 2019
CEO
David Woodhouse
Employees
186
Stock Exchange
NASDAQ
Ticker Symbol
NGM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for NGM stock is "Strong Buy." The 12-month stock price forecast is 37.78, which is an increase of 42.46% from the latest price.

Price Target
$37.78
(42.46% upside)
Analyst Consensus: Strong Buy